Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Purpose of Review: Among the many extra-articular complications of rheumatoid arthritis (RA), interstitial lung disease (ILD) contributes significantly to morbidity and mortality. Prevalence estimates for RA-ILD vary widely depending on the specific clinical, radiographic, and functional criteria used to establish the diagnosis. A key unresolved issue is whether early, subclinical forms of RA-ILD represent a precursor to end stage, fibrotic lung disease. Based on uncertainties surrounding the natural history of RA-ILD, incomplete understanding of underlying disease pathogenesis, and lack of controlled clinical trials, evidence-based therapeutic strategies remain largely undefined. Recent Findings: Correlative clinico-epidemiological studies have identified key risk factors for disease progression. Complementing these findings, the identification of specific molecular and serological markers of RA-ILD has improved our understanding of disease pathogenesis and established the foundation for predictive biomarker profiling. Experience from case series and cohort studies suggests that newer biological agents such as rituximab may be viable treatment options. Summary: RA-ILD continues to have a major impact on “disease intrinsic” morbidity and mortality. Increased understanding of disease pathogenesis and the natural history of subclinical RA-ILD will promote the development of more refined therapeutic strategies.

Original languageEnglish (US)
Article number79
JournalCurrent Rheumatology Reports
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Interstitial Lung Diseases
Rheumatoid Arthritis
Morbidity
Mortality
Controlled Clinical Trials
Biological Factors
Lung Diseases
Uncertainty
Disease Progression
Epidemiologic Studies
Cohort Studies
Joints
Biomarkers
Therapeutics

Keywords

  • Biomarkers
  • Citrullination
  • Idiopathic pulmonary fibrosis (IPF)
  • Interstitial lung disease (ILD)
  • Rheumatoid arthritis (RA)
  • Usual interstitial pneumonia (UIP)

ASJC Scopus subject areas

  • Rheumatology

Cite this

Rheumatoid Arthritis-Associated Interstitial Lung Disease : Current Concepts. / Brito, Yoel; Glassberg Csete, Marilyn K; Ascherman, Dana.

In: Current Rheumatology Reports, Vol. 19, No. 12, 79, 01.12.2017.

Research output: Contribution to journalReview article

@article{84ec239246124edda296c8897c87af4d,
title = "Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts",
abstract = "Purpose of Review: Among the many extra-articular complications of rheumatoid arthritis (RA), interstitial lung disease (ILD) contributes significantly to morbidity and mortality. Prevalence estimates for RA-ILD vary widely depending on the specific clinical, radiographic, and functional criteria used to establish the diagnosis. A key unresolved issue is whether early, subclinical forms of RA-ILD represent a precursor to end stage, fibrotic lung disease. Based on uncertainties surrounding the natural history of RA-ILD, incomplete understanding of underlying disease pathogenesis, and lack of controlled clinical trials, evidence-based therapeutic strategies remain largely undefined. Recent Findings: Correlative clinico-epidemiological studies have identified key risk factors for disease progression. Complementing these findings, the identification of specific molecular and serological markers of RA-ILD has improved our understanding of disease pathogenesis and established the foundation for predictive biomarker profiling. Experience from case series and cohort studies suggests that newer biological agents such as rituximab may be viable treatment options. Summary: RA-ILD continues to have a major impact on “disease intrinsic” morbidity and mortality. Increased understanding of disease pathogenesis and the natural history of subclinical RA-ILD will promote the development of more refined therapeutic strategies.",
keywords = "Biomarkers, Citrullination, Idiopathic pulmonary fibrosis (IPF), Interstitial lung disease (ILD), Rheumatoid arthritis (RA), Usual interstitial pneumonia (UIP)",
author = "Yoel Brito and {Glassberg Csete}, {Marilyn K} and Dana Ascherman",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s11926-017-0701-5",
language = "English (US)",
volume = "19",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "12",

}

TY - JOUR

T1 - Rheumatoid Arthritis-Associated Interstitial Lung Disease

T2 - Current Concepts

AU - Brito, Yoel

AU - Glassberg Csete, Marilyn K

AU - Ascherman, Dana

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose of Review: Among the many extra-articular complications of rheumatoid arthritis (RA), interstitial lung disease (ILD) contributes significantly to morbidity and mortality. Prevalence estimates for RA-ILD vary widely depending on the specific clinical, radiographic, and functional criteria used to establish the diagnosis. A key unresolved issue is whether early, subclinical forms of RA-ILD represent a precursor to end stage, fibrotic lung disease. Based on uncertainties surrounding the natural history of RA-ILD, incomplete understanding of underlying disease pathogenesis, and lack of controlled clinical trials, evidence-based therapeutic strategies remain largely undefined. Recent Findings: Correlative clinico-epidemiological studies have identified key risk factors for disease progression. Complementing these findings, the identification of specific molecular and serological markers of RA-ILD has improved our understanding of disease pathogenesis and established the foundation for predictive biomarker profiling. Experience from case series and cohort studies suggests that newer biological agents such as rituximab may be viable treatment options. Summary: RA-ILD continues to have a major impact on “disease intrinsic” morbidity and mortality. Increased understanding of disease pathogenesis and the natural history of subclinical RA-ILD will promote the development of more refined therapeutic strategies.

AB - Purpose of Review: Among the many extra-articular complications of rheumatoid arthritis (RA), interstitial lung disease (ILD) contributes significantly to morbidity and mortality. Prevalence estimates for RA-ILD vary widely depending on the specific clinical, radiographic, and functional criteria used to establish the diagnosis. A key unresolved issue is whether early, subclinical forms of RA-ILD represent a precursor to end stage, fibrotic lung disease. Based on uncertainties surrounding the natural history of RA-ILD, incomplete understanding of underlying disease pathogenesis, and lack of controlled clinical trials, evidence-based therapeutic strategies remain largely undefined. Recent Findings: Correlative clinico-epidemiological studies have identified key risk factors for disease progression. Complementing these findings, the identification of specific molecular and serological markers of RA-ILD has improved our understanding of disease pathogenesis and established the foundation for predictive biomarker profiling. Experience from case series and cohort studies suggests that newer biological agents such as rituximab may be viable treatment options. Summary: RA-ILD continues to have a major impact on “disease intrinsic” morbidity and mortality. Increased understanding of disease pathogenesis and the natural history of subclinical RA-ILD will promote the development of more refined therapeutic strategies.

KW - Biomarkers

KW - Citrullination

KW - Idiopathic pulmonary fibrosis (IPF)

KW - Interstitial lung disease (ILD)

KW - Rheumatoid arthritis (RA)

KW - Usual interstitial pneumonia (UIP)

UR - http://www.scopus.com/inward/record.url?scp=85033694032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033694032&partnerID=8YFLogxK

U2 - 10.1007/s11926-017-0701-5

DO - 10.1007/s11926-017-0701-5

M3 - Review article

C2 - 29119259

AN - SCOPUS:85033694032

VL - 19

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 12

M1 - 79

ER -